COVID-19
Regístrese
Enfermedades Infecciosas y Microbiología Clínica
Suscribe to the journal
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Is high-dose intravenous fosfomycin safe for the treatment of patients prone to ...
Journal Information
Back to article

Statistics

Follow this link to access the full text of the article

Scientific letter
Is high-dose intravenous fosfomycin safe for the treatment of patients prone to heart failure?
¿Es segura la administración de dosis altas de fosfomicina en pacientes con riesgo de insuficiencia cardiaca?
Irene Cañamares-Orbisa,
Corresponding author
Irene.canamares@gmail.com

Corresponding author.
, José Tiago Silvab, Francisco López-Medranob, Jose Maria Aguadob
a Pharmacy Department, University Hospital 12 Octubre, Avda. Cordoba s/n., 28041 Madrid, Spain
b Infectious Diseases Unit, University Hospital 12 Octubre, Madrid, Spain
Read
5175
Times
was read the article
1855
Total PDF
3320
Total HTML
Share statistics
Article information
ISSN: 0213005X
Original language: English
DOI:10.1016/j.eimc.2014.07.005
The statistics are updated each day
Year/Month Html Pdf Total
2024 April 7 6 13
2024 March 37 16 53
2024 February 53 6 59
2024 January 49 4 53
2023 December 60 6 66
2023 November 40 6 46
2023 October 32 9 41
2023 September 20 4 24
2023 August 12 2 14
2023 July 12 8 20
2023 June 22 5 27
2023 May 10 10 20
2023 April 14 19 33
2023 March 19 7 26
2023 February 21 7 28
2023 January 12 8 20
2022 December 22 7 29
2022 November 29 14 43
2022 October 19 10 29
2022 September 28 19 47
2022 August 36 6 42
2022 July 27 8 35
2022 June 15 9 24
2022 May 26 14 40
2022 April 29 7 36
2022 March 19 11 30
2022 February 30 24 54
2022 January 61 18 79
2021 December 31 18 49
2021 November 26 17 43
2021 October 36 12 48
2021 September 15 23 38
2021 August 38 13 51
2021 July 65 10 75
2021 June 26 4 30
2021 May 33 17 50
2021 April 95 57 152
2021 March 51 28 79
2021 February 41 26 67
2021 January 38 44 82
2020 December 21 13 34
2020 November 22 11 33
2020 October 30 9 39
2020 September 50 13 63
2020 August 43 15 58
2020 July 26 15 41
2020 June 21 10 31
2020 May 28 15 43
2020 April 16 13 29
2020 March 25 23 48
2020 February 32 11 43
2020 January 27 15 42
2019 December 46 33 79
2019 November 23 13 36
2019 October 16 26 42
2019 September 28 24 52
2019 August 22 38 60
2019 July 31 22 53
2019 June 67 35 102
2019 May 135 61 196
2019 April 62 56 118
2019 March 8 17 25
2019 February 17 20 37
2019 January 14 5 19
2018 December 14 14 28
2018 November 15 3 18
2018 October 18 7 25
2018 September 23 10 33
2018 August 8 18 26
2018 July 5 8 13
2018 June 13 9 22
2018 May 18 17 35
2018 April 11 10 21
2018 March 9 14 23
2018 February 7 11 18
2018 January 4 9 13
2017 December 10 10 20
2017 November 7 14 21
2017 October 10 16 26
2017 September 6 11 17
2017 August 18 7 25
2017 July 14 9 23
2017 June 16 33 49
2017 May 23 16 39
2017 April 17 26 43
2017 March 22 65 87
2017 February 40 13 53
2017 January 29 12 41
2016 December 25 8 33
2016 November 33 14 47
2016 October 56 27 83
2016 September 69 20 89
2016 August 38 9 47
2016 July 35 1 36
2016 June 39 24 63
2016 May 21 1 22
2016 April 34 21 55
2016 March 38 19 57
2016 February 34 23 57
2016 January 39 27 66
2015 December 47 19 66
2015 November 35 23 58
2015 October 56 47 103
2015 September 46 28 74
2015 August 38 18 56
2015 July 36 12 48
2015 June 33 15 48
2015 May 58 32 90
2015 April 87 53 140
Show all

Follow this link to access the full text of the article

Subscribe to our newsletter

Publish in
Enfermedades Infecciosas y Microbiología Clínica
Special content about COVID-19
Free access articles
Executive summary of the consensus document on the shared...
Enferm Infecc Microbiol Clin. 2024;42:102-7
Executive Summary of the Consensus Statement of the Spanish...
Enferm Infecc Microbiol Clin. 2020;38:283-8
SARS-CoV-2 infection as trigger multisystem inflammatory...
Enferm Infecc Microbiol Clin. 2021;39:262-4


La Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica agradece la colaboración de:

SOCIOS PROTECTORES

    - Pfizer GEP, S.L.U.
    - Shionogi, S.L.U.
    - AbbVie Spain, S.L.U.
    - Gilead Sciences, S.L.U.
    - Vircell Spain, S.L.U.
    - Roche Diagnostics, S.L.U.
    - ASTRAZENECA FARMACÉUTICA SPAIN, S.A.
    - Qiagen Iberia S.L.
    - Laboratorios ViiV Healthcare, S.L.

SOCIOS PATROCINADORES

- Becton Dickinson S.A.U.
- Janssen-Cilag, S.A.
- Angelini Farmacéutica, S.A.
- Biomerieux España, S,A.U.
- Merck Sharp & Dohme de España, S.A.
- Hologic Iberia, S.L.U.
- Laboratorios Menarini S.A.
- Accelerate Diagnostics S.L.
- Abbott Laboratories, S.A.
- Cepheid Iberia S.L.U.
- Illumina Productos de España. S.L.U.
- DiaSorin Iberia, S.A.
- GlaxoSmithKline, S.A.
- Sysmex España S.L.

Enfermedades Infecciosas y Microbiología Clínica follows the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals

es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos